

12 Jul 2020 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Join us for a quick audio roundup of five useful things to know from *Scrip's* recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around *Scrip's* Five Must-Know Things, in this episode covering the week ended 10 July.

On the menu this time are developments in Alzheimer's and NASH, coronavirus antivirals, [*AbbVie Inc.*](#)'s Japan business and HIV prophylaxis.

Stories mentioned in this episode:

(Also see "[Biogen/Eisai Hit 'Send' On High Stakes BLA For Aducanumab In Alzheimer's Disease](#)" - Scrip, 8 Jul, 2020.)

(Also see "[No Read-Through Expected: NASH Field Unfazed By Intercept's FDA Rejection](#)" - Scrip, 3 Jul, 2020.)

(Also see "[Amid Supply Concerns, EU Approves Gilead's Remdesivir](#)" - Scrip, 3 Jul, 2020.)

(Also see "[AbbVie Eyes Japan Oncology Growth As Humira Biosimilar Looms](#)" - Scrip, 2 Jul, 2020.)

(Also see "[ViiV Thinks It May Get All-Gender Approval For Cabotegravir For PrEP](#)" - Scrip, 7 Jul, 2020.)

[Click here to explore this interactive content online](#) ✨

